Table 4.
The follow-up data of the patients who had neoadjuvant therapy for non-metastatic gastric GISTs
| Patients, n = 34 (%) | |
|---|---|
| Adjuvant imatinib | |
| No | 5 (14.7%) |
| Yes | 29 (85.3%) |
| Duration of adjuvant therapy (months; mean ± SD) | 18.21 ± 12.497 |
| The overall survival (months; mean ± SD) | 37 ± 23.25 |
| The disease-free survival (months; mean ± SD) | 34.53 ± 20.18 |
| Recurrence | |
|
No Yes |
32 (94.1%) 2 (5.9%) |